DRREDDY - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.4
| Stock Code | DRREDDY | Market Cap | 1,06,422 Cr. | Current Price | 1,274 ₹ | High / Low | 1,380 ₹ |
| Stock P/E | 22.9 | Book Value | 378 ₹ | Dividend Yield | 0.63 % | ROCE | 25.8 % |
| ROE | 20.3 % | Face Value | 1.00 ₹ | DMA 50 | 1,273 ₹ | DMA 200 | 1,256 ₹ |
| Chg in FII Hold | -2.35 % | Chg in DII Hold | 2.45 % | PAT Qtr | 90.6 Cr. | PAT Prev Qtr | 387 Cr. |
| RSI | 47.2 | MACD | 6.91 | Volume | 10,47,383 | Avg Vol 1Wk | 11,83,492 |
| Low price | 1,020 ₹ | High price | 1,380 ₹ | PEG Ratio | 0.47 | Debt to equity | 0.13 |
| 52w Index | 70.8 % | Qtr Profit Var | -89.3 % | EPS | 55.6 ₹ | Industry PE | 27.2 |
📊 Dr. Reddy’s Laboratories (DRREDDY) shows strong fundamentals with ROCE (25.8%) and ROE (20.3%), supported by a low debt-to-equity ratio (0.13). Valuation is reasonable with P/E (22.9) below industry average (27.2). Technical indicators are mixed (RSI 47.2 neutral, MACD positive at 6.91, price near 50 & 200 DMA). Despite a sharp decline in quarterly profits, the stock remains a moderately good candidate for swing trading.
💡 Optimal Entry Price: Around ₹1,260–1,280, near support levels.
📈 Exit Strategy (if already holding): Consider exiting near ₹1,350–1,370 if recovery occurs, or cut losses if price falls below ₹1,250 decisively.
Positive
- Strong ROCE (25.8%) and ROE (20.3%) indicate efficient capital use.
- Debt-to-equity ratio of 0.13 shows low leverage.
- EPS of ₹55.6 reflects solid earnings base.
- Dividend yield of 0.63% provides steady income.
- 52-week performance (+70.8%) shows strong momentum.
Limitation
- Quarterly PAT dropped sharply from ₹387 Cr. to ₹90.6 Cr. (-89.3%).
- PEG ratio of 0.47 suggests valuation is not cheap relative to growth.
- Price hovering near DMA levels, showing indecisive trend.
- Volume slightly below average, indicating weaker participation.
Company Negative News
- FII holdings decreased (-2.35%), showing reduced foreign investor confidence.
- Sharp decline in quarterly profits highlights earnings pressure.
Company Positive News
- DII holdings increased (+2.45%), reflecting strong domestic institutional support.
- MACD positive, suggesting potential for short-term recovery momentum.
Industry
- Industry P/E at 27.2 is slightly higher than Dr. Reddy’s, suggesting fair valuation.
- Pharmaceutical sector remains defensive and growth-oriented, supported by global demand for generics and APIs.
Conclusion
⚖️ Dr. Reddy’s Laboratories is fundamentally strong but facing short-term earnings pressure. Technicals are mixed, with neutral RSI and positive MACD. Swing traders may cautiously enter near support (~₹1,260–1,280) and exit near resistance (~₹1,350–1,370). Conservative traders should wait for earnings stability before entering.